医学
生活质量(医疗保健)
CD19
内科学
免疫学
疾病
汽车T细胞治疗
系统性红斑狼疮
红斑狼疮
T细胞
物理疗法
细胞疗法
年轻人
自身免疫性疾病
重症监护医学
结缔组织病
临床试验
免疫病理学
梅德林
医疗保健
社会经济地位
痹症科
儿科
全身性疾病
肿瘤科
作者
Jule Taubmann,Melanie Hagen,Fabian Müller,Andreas Wirsching,Selahattin Alp Temiz,Simon Völkl,Michael Aigner,Ricardo Grieshaber‐Bouyer,Andréas Mackensen,Georg Andreas Schett
标识
DOI:10.3899/jrheum.2024-1301
摘要
OBJECTIVE: Patients with systemic lupus erythematosus (SLE) require long-term treatment and experience reduced quality of life (QOL). CD19 chimeric antigen receptor (CAR) T cell therapy can achieve sustained drug-free remission in patients with SLE. The impact of CAR T cell therapy on QOL and direct healthcare costs has not been evaluated. Here, we analyzed longitudinal QOL before and after CAR T cell therapy and performed an assessment of direct healthcare costs. METHODS: Physical and mental health were assessed using the standardized 36-item Short Form Health Survey before and 1 year after treatment. Annual direct healthcare costs were analyzed based on inpatient admissions, emergency department visits, outpatient visits, and prescription drug costs in the German healthcare service. RESULTS: A preliminary analysis was conducted on 8 patients with SLE (7 female, 1 male; age range 19-38 years) who received CAR T cell therapy and who were followed for > 2 years. CAR T cell therapy resulted in improvement in the QOL in all patients. The most notable improvement was observed in physical health (from 22.4% to 75.5%), although mental health also improved (from 24.7% to 63%). QOL values rose to the level of a healthy comparison cohort. Additionally, CAR T cell therapy led to a substantial decrease in annual direct healthcare costs from €29,672/year (US $34,353/year) to €3094/year ($3582/year) after treatment. CONCLUSION: In addition to clinical efficacy, in this preliminary cohort, CD19 CAR T cell treatment improves QOL in patients with SLE and may substantially reduce the direct socioeconomic burden associated with active disease by > 90%.
科研通智能强力驱动
Strongly Powered by AbleSci AI